Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548053 | 0.76 | HPGD (0.56) | HPGDRAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL2782422 | 0.75 | FFAR1 (0.51) | HPGDRAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL28184652 | 0.73 | FFAR1 (0.50) | HPGDRAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL2439080 | 0.72 | FAAH (0.57) | HPGDRAB9ACYP3A4CYP2C19KMT2A | |
| SCHEMBL11586847 | 0.72 | EPHX2 (0.56) | HPGDCYP2C19ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11142933 | 0.72 | FFAR1 (0.49) | HPGDRAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL6449911 | 0.71 | FFAR1 (0.51) | HPGDRAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL237090 | 0.70 | FFAR1 (0.70) | HPGDRAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL7398650 | 0.70 | ACHE (0.60) | HPGDRAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1149768 | 0.70 | FFAR1 (0.70) | HPGDRAB9ACYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309702-B2 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; Alzheimer's disease | AVERA PHARMACEUTICALS, INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-7001908-B2 | Arylpiperazines having activity at the serotonin 1A receptor | AVERA PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20060009464-A1 | Arylpiperazines having activity at the serotonin 1A receptor | ELI LILLY AND COMPANY | 2006-01-12 | — | — | US | disclosed |
| US-20050282817-A1 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity | NOKIA CORPORATION (FI) | 2005-12-22 | — | — | US | disclosed |
| US-6946579-B2 | Arylpiperazines having activity at the serotonin 1A receptor | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| EP-0924205-B1 | Arylpiperazines having activity at the serotonin 1a receptor | LILLY CO ELI (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1514559-A1 | Arylpiperazines having activity at the serotonin 1a receptor | Eli Lilly and Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040049083-A1 | 3-carbocycle carbonyl-3-phenylpropionaldehyde intermediates and preparation by alkylating a carbocycle benzyl ketone with an allyl halide and oxidizing the product | ELI LILLY AND COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-20040044009-A1 | Drug abuse; cental nervous system disorders; cognition activators | ELI LILLY AND COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-6660859-B2 | Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases | ELI LILLY AND COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-6645967-B2 | Administering to a patient a serotonin reuptake inhibitor in combination with an effective amount of arylpiperazines having activity at the serotonin 1A receptor | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| US-20030027831-A1 | Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases | XU YAO-CHANG (US) | 2003-02-06 | — | — | US | disclosed |
| US-6514976-B2 | For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20030008879-A1 | For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety | KOHLMAN DANIEL TIMOTHY (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020169170-A1 | Administering to a patient a serotonin reuptake inhibitor in combination with an effective amount of arylpiperazines having activity at the serotonin 1A receptor | GODFREY ALEXANDER GLENN (US) | 2002-11-14 | — | — | US | disclosed |
| US-6358958-B2 | MONO OR BICYCLIC ARYL OR HETERARYL SUBSTITUTED PIPERIZIN DERIVATIVES USEFUL FOR TREATING ANXIETY, DEPRESSION, HYPERTENSION, COGNITIVE DISORDER, PSYCHOSIS, SLEEP DISORDER, BRAIN TRAUMA, MEMORY LOSS, DRUG ABUSE, MIGRAINE AND OBESITY | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-20010003749-A1 | Mono or bicyclic aryl or heteraryl substituted piperizin derivatives useful for treating anxiety, depression, hypertension, cognitive disorder, psychosis, sleep disorder, brain trauma, memory loss, drug abuse, migraine and obesity | GODFREY ALEXANDER GLENN (US) | 2001-06-14 | — | — | US | disclosed |
| US-6239135-B1 | ALLEVIATING THE SYMPTOMS OF NICOTINE AND TOBACCO WITHDRAWAL. | ELI LILLY AND COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-1999031077-A1 | ARYLPIPERAZINES HAVING ACTIVITY AT THE SEROTONIN 1A RECEPTOR | ELI LILLY AND COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0924205-A1 | Arylpiperazines having activity at the serotonin 1a receptor | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027831-A1 | Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases | HTR2C, HTR3C, HCRTR1 | HPGD 2036/4885RAB9A 2806/4885CYP3A4 1465/4885 |
| US-20060009464-A1 | Arylpiperazines having activity at the serotonin 1A receptor | HTR1A, HTR2A, HTR3A | HPGD 1099/4885RAB9A 2936/4885CYP3A4 678/4885 |
| US-20040049083-A1 | 3-carbocycle carbonyl-3-phenylpropionaldehyde intermediates and preparation by alkylating a carbocycle benzyl ketone with an allyl halide and oxidizing the product | HTR3C, HTR3A, HTR2C | HPGD 492/4885RAB9A 4542/4885CYP3A4 252/4885 |
| US-20010003749-A1 | Mono or bicyclic aryl or heteraryl substituted piperizin derivatives useful for treating anxiety, depression, hypertension, cognitive disorder, psychosis, sleep disorder, brain trauma, memory loss, drug abuse, migraine and obesity | HTR1A, HTR2C, HTR3B | HPGD 560/4885RAB9A 3759/4885CYP3A4 702/4885 |
| US-20020169170-A1 | Administering to a patient a serotonin reuptake inhibitor in combination with an effective amount of arylpiperazines having activity at the serotonin 1A receptor | HTR3C, TPH1, HTR6 | HPGD 1881/4885RAB9A 3262/4885CYP3A4 530/4885 |
| US-20030008879-A1 | For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety | HTR1A, HTR1B, HTR3A | HPGD 422/4885RAB9A 3988/4885CYP3A4 1474/4885 |
| US-20040044009-A1 | Drug abuse; cental nervous system disorders; cognition activators | HTR6, HTR1A, CNR1 | HPGD 2071/4885RAB9A 3956/4885CYP3A4 943/4885 |
| US-20050282817-A1 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity | HTR3A, HTR3C, HTR1A | HPGD 1368/4885RAB9A 4601/4885CYP3A4 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.